Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 85

Sort by

Sort Order Select

Journal Articles

Prognostic Impact of Response Kinetics and Influencing Factors in Multiple Myeloma Patients Treated with Carfilzomib- or Ixazomib-Based Treatment

Blood (2024) 144 (Supplement 1): 4698.

https://doi.org/10.1182/blood-2024-205164

Published: 2024

Journal Articles

Multicenter Retrospective Analysis on the Clinical Benefit of Post-Transplant Tyrosine Kinase Inhibitor (TKI) Maintenance Therapy in Ph-Positive Acute Lymphoblastic Leukemia Suggests Improved GvHD-Free, Relapse Free Survival and Non-Relapse Mortality, but Not the Risk of Relapse

Eshrak Al-Shaibani, Yu Cai, Xianmin Song, Mohsen Al Zahrani, Mohamed Elemary, Muhned Alhumaid, Hanan Alkhaldi, Ayman Saad, Francesca Biavasco, Robert Zeiser, Joon Ho Moon, Sang Kyun Sohn, Jonas Mattsson, Dennis Dong Hwan Kim

Blood (2024) 144 (Supplement 1): 4930.

https://doi.org/10.1182/blood-2024-211761

Published: 2024

Journal Articles

Multicenter, Real-World Experience Study of FLT3-Inhibitor Post-Transplant Maintenance Therapy Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia with FLT3-ITD

Yomna Eissa, Hyeoung-Joon Kim, Joon Ho Moon, Robert Zeiser, Francesca Biavasco, Christopher Lemieux, Mohamed Elemary, Varun Mehra, Mili Shah, Ahmed Alotaibi, Yu Cai, Xianmin Song, Jae-Sook Ahn, Sang Kyun Sohn, Mohsen Al Zahrani, Muhned Alhumaid, Hee-Je Kim, Dennis Dong Hwan Kim

Blood (2024) 144 (Supplement 1): 778.

https://doi.org/10.1182/blood-2024-208622

Published: 2024

Journal Articles

Nationwide Analysis on Incidences and Treatment Outcomes of T-Cell Subtype Lymphomas Based on Health Insurance Review & Assessment Service

Jungmin Lee, Youngeun Jang, Yunji Lee, Hee Jeong Cho, Joon Ho Moon, Young Rok Do, Sang Kyun Sohn, Dong Won Baek

Blood (2024) 144 (Supplement 1): 6397.

https://doi.org/10.1182/blood-2024-203187

Published: 2024

Journal Articles

Multicenter Survey on the Practice Patterns of Post-Transplant Maintenance Treatment in FLT3-ITD Acute Myeloid Leukemia and Philadelphia Positive Acute Lymphoblastic Leukemia: What Is the Common Institutional Policy for Duration of Therapy?

Blood (2024) 144 (Supplement 1): 7418.

https://doi.org/10.1182/blood-2024-206153

Published: 2024

Journal Articles

Cardiovascular Toxicity after Carfilzomib, Lenalidomide, and Dexamethasone Combination Chemotherapy in the Real-World 364 Asian Multiple Myeloma Patients on Behalf of the Korean Multiple Myeloma Working Party (KMM2201 study)

Blood (2023) 142 (Supplement 1): 6675.

https://doi.org/10.1182/blood-2023-174439

Published: 2023

Journal Articles

Multicenter, Prospective Study to Investigate the Efficacy and Safety of Intravenous-Immunoglobulin Therapy in Elderly Patients with Diffuse Large B Cell Lymphoma Treated with R-Mini-CHOP

Dong Won Baek, Ga-Young Song, Hyukjin Choi, Ho Sup Lee, Young Rok Do, Ji Hyun Lee, Joon Ho Moon, Deok-Hwan Yang

Blood (2023) 142 (Supplement 1): 2327.

https://doi.org/10.1182/blood-2023-189114

Published: 2023

Journal Articles

Combinatorial Optimization of Chemotherapeutic Agents on T-Cell Acute Lymphoblastic Leukemia

Juhyung Kim, Hong Duc Nguyen Thi, Minh Tan Le, Hee Jeong Cho, Joon Ho Moon, Sang Kyun Sohn, Dong Won Baek

Blood (2023) 142 (Supplement 1): 5797.

https://doi.org/10.1182/blood-2023-188246

Published: 2023

Journal Articles

The Co-Occurrence of bZIP in-Frame CEBPA -Mutation with Unfavorable Genetic Abnormalities Is Associated with a Poor Prognosis in Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 6035.

https://doi.org/10.1182/blood-2023-180499

Published: 2023

Journal Articles

Risk Stratification for Elderly Patients with Diffuse Large B-Cell Lymphoma Integrating Simplified Geriatric Assessment: A Prospective, Multicenter, Cohort Study

Ho-Young Yhim, Yong Park, Jeong-A Kim, Ho-Jin Shin, Young Rok Do, Joon Ho Moon, Min Kyoung Kim, Won Sik Lee, Dae Sik Kim, Myung-Won Lee, Yoon Seok Choi, Seong Hyun Jeong, Kyoung Ha Kim, Chang-Hoon Lee, Ga-Young Song, Jae-Yong Kwak, Deok-Hwan Yang

Blood (2022) 140 (Supplement 1): 6719–6720.

https://doi.org/10.1182/blood-2022-159929

Published: 2022

Journal Articles

Role of Autologous or Allogeneic Stem Cell Transplantation in Patients with Peripheral T Cell Lymphomas (PTCLs)

Blood (2022) 140 (Supplement 1): 6592–6593.

https://doi.org/10.1182/blood-2022-171149

Published: 2022

Journal Articles

Prognostic Predictability of 2022 European Leukemianet (ELN) Risk Stratification in the Real World

Blood (2022) 140 (Supplement 1): 1018–1019.

https://doi.org/10.1182/blood-2022-166182

Published: 2022

Journal Articles

Multicenter Phase II Study to Evaluate Therapeutic Efficacy of Imatinib Mesylate in Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease

Dong Won Baek, Sr., Joon Ho Moon, Jae-Sook Ahn, Seong Kyu Park, Ik Chan Song, Ho-Sup Lee, Won Sik Lee, Jong Ho Won, Hong Ghi Lee, June-Won Cheong, Yeung-Chul Mun, Chul W. Jung, Je-Hwan Lee, Hyeoung-Joon Kim, Sang Kyun Sohn

Blood (2021) 138 (Supplement 1): 2889.

https://doi.org/10.1182/blood-2021-154470

Published: 2021

Journal Articles

Development of a New Risk Stratification System for Patients with Newly Diagnosed Multiple Myeloma Using R-ISS and 18F-FDG PET/CT

Blood (2021) 138 (Supplement 1): 3757.

https://doi.org/10.1182/blood-2021-152008

Published: 2021

Journal Articles

High Residual Allelic Burden Increases Leukemic Transformation Irrespective of Clinical Response in Patients with Lower Risk Myelodysplastic Syndrome Treated with Azacitidine

Joon Ho Moon, MD, Hee Jeong Cho, MD, Dong Won Baek, MD, Sang Kyun Sohn, MD PhD, Jae-Sook Ahn, Seo-Yeon Ahn, MD, Seunghyun Choi, PhD, Kyoung Ha Kim, MD PhD, Taehyung Kim, Zhaolei Zhang, PhD, Hyeoung-Joon Kim, MD PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2019) 134 (Supplement_1): 4263.

https://doi.org/10.1182/blood-2019-130428

Published: 2019

Journal Articles

Clinical Impact of 18 f-FDG PET/CT As a Valuable Prognostic Tool for the Newly Diagnosed Multiple Myeloma with Extramedullary Disease

Dong Won Baek, MD, Hee Jeong Cho, Sang Kyun Sohn, MD PhD, Sung-Hoon Jung, MD, Hong chae Moon, Joon Ho Moon, MD

Blood (2019) 134 (Supplement_1): 3142.

https://doi.org/10.1182/blood-2019-129831

Published: 2019

Journal Articles

RNA Sequencing-Based Measurement of Fusion-Transcript for Minimal Residual Disease (MRD) Monitoring in Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)

Taehyung Kim, MSc, Joon Ho Moon, MD, Jae-Sook Ahn, MD PhD, Marc S. Tyndel, B. Eng, Seung-Shin Lee, MD, Seo-Yeon Ahn, MD, Sung-Hoon Jung, MD, Deok-Hwan Yang, MD PhD, Je-Jung Lee, MD PhD, Seunghyun Choi, PhD, Ja-yeon Lee, MSc, Yoojin Lee, MDPhD, Sang Kyun Sohn, MD PhD, Zhaolei Zhang, PhD, Hyeoung-Joon Kim, MD PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2018) 132 (Supplement 1): 2669.

https://doi.org/10.1182/blood-2018-99-112037

Published: 2018

Journal Articles

Benefit of Two Additional Cycles of Bortezomib/Thalidomide/Dexamethasone (VTD) Induction Therapy Compared to Four Cycles of VTD for Newly Diagnosed Multiple Myeloma

Yoojin Lee, MD PhD, Kihyun Kim, MD PhD, Sang Kyun Sohn, MDPhD, Dongwon Back, MD, Joon Ho Moon, MD, Je-Jung Lee, MD PhD, Jae-Cheol Jo, MD, Won-Sik Lee, MD, Ho-Jin Shin, MD PhD, Sung-Hyun Kim, MD PhD, Ji Hyun Lee, MD PhD, Sung Hwa Bae, MD, Min Kyoung Kim, MD PhD, Ho Sup Lee, MD, Chang-Ki Min, MD PhD

Blood (2018) 132 (Supplement 1): 3252.

https://doi.org/10.1182/blood-2018-99-113229

Published: 2018

Journal Articles

Identification of High Risk Group for Leukemic Transformation in Higher Risk MDS Patients Using Targeted RNA-Sequencing: Hematopoietic Stem Cell Signature As a High Risk Profile for Leukemic Transformation

Joon Ho Moon, MD, Taehyung Kim, MSc, Jae-Sook Ahn, MD PhD, Seo-Yeon Ahn, MD, Sung-Hoon Jung, MD, Deok-Hwan Yang, MD, Je-Jung Lee, MD PhD, Seunghyun Choi, PhD, Yoojin Lee, MD PhD, Sang Kyun Sohn, MD PhD, Hyeoung-Joon Kim, MD PhD, Zhaolei Zhang, PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2018) 132 (Supplement 1): 4361.

https://doi.org/10.1182/blood-2018-99-116241

Published: 2018

Journal Articles

Residual Allelic Burden Measured By Next-Generation Sequencing (NGS) at Remission Provides Limited Prognostic Value to Predict Relapse and Long-Term Outcome in Core Binding Factor Acute Myeloid Leukemia (CBF-AML)

Taehyung Kim, MSc, Joon Ho Moon, MD, Jae-Sook Ahn, MD PhD, Marc S. Tyndel, B. Eng, Seung-Shin Lee, MD, Seo-Yeon Ahn, MD, Sung-Hoon Jung, MD, Deok-Hwan Yang, MD, Je-Jung Lee, MD PhD, Seunghyun Choi, PhD, Ja-yeon Lee, MSc, Yoojin Lee, MDPhD, Sang Kyun Sohn, MDPhD, Hyeoung-Joon Kim, MD PhD, Zhaolei Zhang, PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2018) 132 (Supplement 1): 1391.

https://doi.org/10.1182/blood-2018-99-112906

Published: 2018

NARROW

Prognostic Impact of Response Kinetics and Influencing Factors in Multiple Myeloma Patients Treated with Carfilzomib- or Ixazomib-Based Treatment

Multicenter Retrospective Analysis on the Clinical Benefit of Post-Transplant Tyrosine Kinase Inhibitor (TKI) Maintenance Therapy in Ph-Positive Acute Lymphoblastic Leukemia Suggests Improved GvHD-Free, Relapse Free Survival and Non-Relapse Mortality, but Not the Risk of Relapse

Multicenter, Real-World Experience Study of FLT3-Inhibitor Post-Transplant Maintenance Therapy Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia with FLT3-ITD

Nationwide Analysis on Incidences and Treatment Outcomes of T-Cell Subtype Lymphomas Based on Health Insurance Review & Assessment Service

Multicenter Survey on the Practice Patterns of Post-Transplant Maintenance Treatment in FLT3-ITD Acute Myeloid Leukemia and Philadelphia Positive Acute Lymphoblastic Leukemia: What Is the Common Institutional Policy for Duration of Therapy?

Cardiovascular Toxicity after Carfilzomib, Lenalidomide, and Dexamethasone Combination Chemotherapy in the Real-World 364 Asian Multiple Myeloma Patients on Behalf of the Korean Multiple Myeloma Working Party (KMM2201 study)

Multicenter, Prospective Study to Investigate the Efficacy and Safety of Intravenous-Immunoglobulin Therapy in Elderly Patients with Diffuse Large B Cell Lymphoma Treated with R-Mini-CHOP

Combinatorial Optimization of Chemotherapeutic Agents on T-Cell Acute Lymphoblastic Leukemia

The Co-Occurrence of bZIP in-Frame CEBPA -Mutation with Unfavorable Genetic Abnormalities Is Associated with a Poor Prognosis in Acute Myeloid Leukemia

Risk Stratification for Elderly Patients with Diffuse Large B-Cell Lymphoma Integrating Simplified Geriatric Assessment: A Prospective, Multicenter, Cohort Study

Role of Autologous or Allogeneic Stem Cell Transplantation in Patients with Peripheral T Cell Lymphomas (PTCLs)

Prognostic Predictability of 2022 European Leukemianet (ELN) Risk Stratification in the Real World

Multicenter Phase II Study to Evaluate Therapeutic Efficacy of Imatinib Mesylate in Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease

Development of a New Risk Stratification System for Patients with Newly Diagnosed Multiple Myeloma Using R-ISS and 18F-FDG PET/CT

High Residual Allelic Burden Increases Leukemic Transformation Irrespective of Clinical Response in Patients with Lower Risk Myelodysplastic Syndrome Treated with Azacitidine

Clinical Impact of 18 f-FDG PET/CT As a Valuable Prognostic Tool for the Newly Diagnosed Multiple Myeloma with Extramedullary Disease

RNA Sequencing-Based Measurement of Fusion-Transcript for Minimal Residual Disease (MRD) Monitoring in Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)

Benefit of Two Additional Cycles of Bortezomib/Thalidomide/Dexamethasone (VTD) Induction Therapy Compared to Four Cycles of VTD for Newly Diagnosed Multiple Myeloma

Identification of High Risk Group for Leukemic Transformation in Higher Risk MDS Patients Using Targeted RNA-Sequencing: Hematopoietic Stem Cell Signature As a High Risk Profile for Leukemic Transformation

Residual Allelic Burden Measured By Next-Generation Sequencing (NGS) at Remission Provides Limited Prognostic Value to Predict Relapse and Long-Term Outcome in Core Binding Factor Acute Myeloid Leukemia (CBF-AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only